InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, and Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP),...
Thinly traded nano cap Aquinox Pharmaceuticals ( AQXP -14.6% ) is down on almost a 14x surge in volume in reaction its planned merger with privately held Seattle-based Neoleukin Therapeutics . More news on: Aquinox Pharmaceuticals, Inc., Healthcare stocks news, Merger & acquisition ...
• Combined company capitalized with approximately $65M to develop novel immunotherapies • Sophisticated computational platform enables new class of de novo protein therapeutics • Lead program, NL-201, is a potent IL-2/IL-15 agonist with favorable t...
News, Short Squeeze, Breakout and More Instantly...
Aquinox Pharmaceuticals Inc. Company Name:
AQXP Stock Symbol:
NASDAQ Market:
Aquinox Pharmaceuticals Inc. Website:
Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, and Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP),...
• Combined company capitalized with approximately $65M to develop novel immunotherapies • Sophisticated computational platform enables new class of de novo protein therapeutics • Lead program, NL-201, is a potent IL-2/IL-15 agonist with favorable t...